Medifast (MED) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares.
View MED analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price objectives for Medifast's shares. Their MED share price forecasts range from $71.00 to $150.00. On average, they predict the company's share price to reach $110.50 in the next twelve months. This suggests a possible upside of 34.3% from the stock's current price.
View analysts price targets for MED or view top-rated stocks among Wall Street analysts.

Medifast's stock was trading at $115.35 at the beginning of 2023. Since then, MED stock has decreased by 28.7% and is now trading at $82.25.
View the best growth stocks for 2023 here.

Medifast saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,730,000 shares, an increase of 9.5% from the April 15th total of 1,580,000 shares. Based on an average daily trading volume, of 238,500 shares, the days-to-cover ratio is currently 7.3 days. Approximately 16.3% of the shares of the company are sold short.
View Medifast's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our MED earnings forecast.

Medifast, Inc. (NYSE:MED) released its quarterly earnings results on Monday, May, 1st. The specialty retailer reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $1.27. The specialty retailer earned $349 million during the quarter, compared to analyst estimates of $319.50 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 106.70%. Medifast's revenue for the quarter was down 16.4% on a year-over-year basis. During the same period last year, the company posted $3.59 earnings per share.

Medifast declared a quarterly dividend on Thursday, March 16th. Stockholders of record on Tuesday, March 28th will be paid a dividend of $1.65 per share on Tuesday, May 9th. This represents a $6.60 annualized dividend and a yield of 8.02%. The ex-dividend date is Monday, March 27th. This is an increase from the stock's previous quarterly dividend of $1.64.
Read our dividend analysis for MED.

ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap Consumer Staples ETF (PSCC), First Trust SMID Cap Rising Dividend Archievers ETF (SDVY), Roundhill Acquirers Deep Value ETF (DEEP), VictoryShares US Small Cap High Div Volatility Wtd ETF (CSB), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS), Pacer US Small Cap Cash Cows 100 ETF (CALF),

Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 7.90%. MED has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 51.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MED will have a dividend payout ratio of 67.62% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MED.

Medifast updated its second quarter earnings guidance on Monday, May, 1st. The company provided earnings per share guidance of $1.32-$1.44 for the period, compared to the consensus EPS estimate of $2.82. The company issued revenue guidance of $250-$270 million, compared to the consensus revenue estimate of $313.20 million.

44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.45%), Renaissance Technologies LLC (5.98%), State Street Corp (3.49%), Dimensional Fund Advisors LP (3.06%), Principal Financial Group Inc. (2.05%) and Geode Capital Management LLC (2.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MED stock can currently be purchased for approximately $82.25.

Medifast (NYSE:MED) has a market capitalization of $895.70 million and generates $1.60 billion in revenue each year. The specialty retailer earns $143.57 million in net income (profit) each year or $12.77 on an earnings per share basis.

The company employs 984 workers across the globe.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The official website for the company is www.medifast1.com. The specialty retailer can be reached via phone at (410) 581-8042, via email at ir@choosemedifast.com, or via fax at 410-581-8070.